The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice

被引:29
作者
Burns, Ted M. [1 ]
机构
[1] Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA
来源
MYASTHENIA GRAVIS AND RELATED DISORDERS I | 2012年 / 1274卷
关键词
MG composite; myasthenia gravis; outcome measures; MGC; MG; MYCOPHENOLATE-MOFETIL; RECOMMENDATIONS; CYCLOSPORINE; RELIABILITY; VALIDATION; STANDARDS; IVIG;
D O I
10.1111/j.1749-6632.2012.06812.x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The myasthenia gravis composite (MGC) was constructed by selecting the best performing items from three commonly used, MG-specific scales. The response categories of the items were subsequently weighted for importance. The MGC, which takes less than five minutes to complete, is made up of three ocular, three bulbar, one respiratory, one neck, and two limb items. After its construction, the MGC was validated in an 11-center scale validity study. During the validation study, which included test-retest analysis, it was determined that a 3-point improvement in MGC score reliably indicates clinical improvement. A 3-point improvement in MGC also appears to be meaningful to the patient. Rasch analysis of the MGC confirmed that all 10 items belong and can be summed to provide a total score, and that the weights given to the response categories of the items are appropriate.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 32 条
  • [1] Standards of measurements in myasthenia gravis
    Barohn, RJ
    [J]. MYASTHENIA GRAVIS AND RELATED DISORDERS: BIOCHEMICAL BASIS FOR DISEASE OF THE NEUROMUSCULAR JUNCTION, 2003, 998 : 432 - 439
  • [2] Reliability testing of the quantitative myasthenia gravis score
    Barohn, RJ
    McIntire, D
    Herbelin, L
    Wolfe, GI
    Nations, S
    Bryan, WW
    [J]. MYASTHENIA GRAVIS AND RELATED DISEASES: DISORDERS OF THE NEUROMUSCULAR JUNCTION, 1998, 841 : 769 - 772
  • [3] Comparison of IVIg and PLEX in patients with myasthenia gravis
    Barth, D.
    Nouri, M. Nabavi
    Ng, E.
    Nwe, P.
    Bril, V.
    [J]. NEUROLOGY, 2011, 76 (23) : 2017 - 2023
  • [4] Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity
    Bedlack, RS
    Simel, DL
    Bosworth, H
    Samsa, G
    Tucker-Lipscomb, B
    Sanders, DB
    [J]. NEUROLOGY, 2005, 64 (11) : 1968 - 1970
  • [5] Recommendations for myasthenia gravis clinical trials
    Benatar, Michael
    Sanders, Donald B.
    Burns, Ted M.
    Cutter, Gary R.
    Guptill, Jeffrey T.
    Baggi, Fulvio
    Kaminski, Henry J.
    Mantegazza, Renato
    Meriggioli, Matthew N.
    Quan, Joanne
    Wolfe, Gil I.
    [J]. MUSCLE & NERVE, 2012, 45 (06) : 909 - 917
  • [6] THE MG-QOL15 FOR FOLLOWING THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH MYASTHENIA GRAVIS
    Burns, Ted M.
    Grouse, C. K.
    Wolfe, Gil I.
    Conaway, Mark R.
    Sanders, Donald B.
    [J]. MUSCLE & NERVE, 2011, 43 (01) : 14 - 18
  • [7] HISTORY OF OUTCOME MEASURES FOR MYASTHENIA GRAVIS
    Burns, Ted M.
    [J]. MUSCLE & NERVE, 2010, 42 (01) : 5 - 13
  • [8] The MG Composite A valid and reliable outcome measure for myasthenia gravis
    Burns, Ted M.
    Conaway, Mark
    Sanders, Donald B.
    [J]. NEUROLOGY, 2010, 74 (18) : 1434 - 1440
  • [9] CONSTRUCT AND CONCURRENT VALIDATION OF THE MG-QOL15 IN THE PRACTICE SETTING
    Burns, Ted M.
    Grouse, C. K.
    Conaway, Mark R.
    Sanders, Donald B.
    [J]. MUSCLE & NERVE, 2010, 41 (02) : 219 - 226
  • [10] CONSTRUCTION OF AN EFFICIENT EVALUATIVE INSTRUMENT FOR MYASTHENIA GRAVIS: THE MG COMPOSITE
    Burns, Ted M.
    Conaway, Mark R.
    Cutter, Gary R.
    Sanders, Donald B.
    [J]. MUSCLE & NERVE, 2008, 38 (06) : 1553 - 1562